Kailera Therapeutics
CA - San DiegoBiotechnology
Focus: Kailera Therapeutics is a clinical-stage biotech focused on peptide and small molecule therapeutics targeting metabolic diseases, with a recently public listing on Nasdaq following a strong 60%+ IPO debut in April 2026.
Profile data last refreshed 37m ago · AI intelligence enriched 2mo ago
Open Jobs
19
Should You Work at Kailera Therapeutics?
AI assessmentKailera represents a growth-stage opportunity for professionals seeking equity upside and the chance to build commercial infrastructure from clinical success, but with execution risk typical of newly public biotech.
Why Work Here
- Active clinical development pipeline with 3 Phase 3 programs in obesity, a high-value therapeutic area with significant commercial potential
Data completeness
3/9 — Basic
Company HealthStrong
Pipeline
Late-stage
3 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Growing
Jobs increasing
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
KAI-9531
Healthy VolunteersClinical Trials (2)
NCT07458269Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes
Phase 2Help build intelligence for Kailera Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.